EastGroup Properties vs Rayonier
EGP and RYN side by side, both in miscellaneous investing. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EGP and RYN compare
EastGroup Properties is the larger company, worth 1.7 times as much as Rayonier ($10.6B against $6.4B).
On earnings, EastGroup Properties is cheaper: it trades at 33.5× trailing earnings, against 47.9× for Rayonier.
EastGroup Properties grew revenue faster over the last twelve months (10.4% versus 0.44% for Rayonier).
Both pay dividends: EastGroup Properties yields 3.2% and Rayonier 4.9%.
Rayonier scores higher on the StockData Score (8 against 7 for EastGroup Properties), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EGP | RYN |
|---|---|---|
| Size and price | ||
| Market cap | $10.6B | $6.4B |
| Share price | $197.94 | $21.55 |
| Change, 1 year | 12.0% | −4.5% |
| Change, 5 years | −3.7% | −46.1% |
| Beta (5Y) | 0.81 | 0.69 |
| Employees | 103 | 285 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 3 (better) | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 2 | 3 (better) |
| Valuation | ||
| P/E | 33.5× (better) | 47.9× |
| P/S | 13.8× | 6.6× (better) |
| P/B | 3.0× | 1.2× (better) |
| EV/EBITDA | – | 136× |
| PEG | 8.93 | 0.79 (better) |
| Fair value | $159.05 | $14.84 |
| Margin of safety | −24.5% (better) | −45.2% |
| Growth | ||
| Revenue growth (TTM) | 10.4% (better) | 0.44% |
| Revenue growth, 5Y average | 14.7% (better) | −10.8% |
| Net income growth (TTM) | – | −90.0% |
| EPS growth (TTM) | 23.9% (better) | −90.9% |
| EPS growth, 5Y average | 12.0% | 62.2% (better) |
| Profitability | ||
| Gross margin | – | 23.7% |
| Operating margin | – | 6.0% |
| Net margin | – | 7.8% |
| Return on equity | – | 2.0% |
| Return on invested capital | – | 1.3% |
| Financial health | ||
| Debt / equity | – | 0.36 |
| Net debt / EBITDA | – | 25.02 |
| Interest coverage | – | 1.3× |
| Current ratio | – | 3.56 |
| Altman Z-score | 3.03 (better) | 1.95 |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Dividend yield | 3.2% | 4.9% (better) |
| Payout ratio | – | 393% |
| Years of dividend growth | 14 (better) | 0 |
| Dividend growth, 5Y average | 13.9% | 18.2% (better) |
| Buyback yield | −0.65% | 0.05% (better) |
| Shareholder yield | 2.6% | 4.9% (better) |
| Ownership | ||
| Held by institutions | 102% | 94.2% |
| Held by insiders | 1.0% | 1.0% |
| Insider net buying, 12 months | −$421K (better) | −$3.8M |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 8.6% | 4.9% |
Go deeper
- EGP stock overview
- EGP income statement
- EGP valuation and score
- RYN stock overview
- RYN income statement
- RYN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.